Articles related to Family Medicine/General Practice

The median time to recovery in a group of 1,800 vaccinated and unvaccinated adults (median age: 48 years) was essentially the same whether the patients received ivermectin or placebo: 12 and 13 days, respectively. Death rate was slightly higher in the ivermectin group and rates of pneumonia and VTE were slightly higher in the placebo group.

This study of 2,500 adults receiving mechanical ventilation randomized 1/3 were assigned to an exigent saturation target pf 90%, 1/3 to a target of 94%, and 1/3 to a target of 98%. The median number of ventilator-free days was 20, 21, and 21 for the three target groups, respectively. In-hospital death by day 28 was 34.8%, 34.0%, and 33.2% for the three groups, respectively.

Misunderstandings and misperceptions about migraine persist, leading to misdiagnosis and less-than-optimal management. In this video, migraine experts seek to update the primary care provider on the current understanding of the disease, and the role of gepants, ditans, triptans, calcitonin gene-related peptide antibodies, and other therapies.

In this randomized trial from Poland, Norway, Sweden, and the Netherlands, the study population of approximately 85,000 individuals were randomly assigned to colonoscopy screening or usual care. The risk of colorectal cancer at 10 years was 18% lower in the screening cohort.

This broad review of recent studies in women’s health topics aims to help the primary care physician in discussing and guiding therapy for women in topics from cardiovascular disease to pelvic pain. The review covers such questions as: How does migraine with aura affect CVD risk in women? How do you respond to patient questions about fracture risk and bisphosphonates? Are antidepressants safe for women who are considering pregnancy? Is gabapentin effective for chronic pelvic pain?

The obesity epidemic affects millions of patients around the world, but a new treatment option may be a game-changer for the treatment landscape. Lead author of the STEP 8 clinical trial, Dr. Domenica Rubino, shares insights from trial and how these key clinical findings could change obesity management.